Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule pharmacological chaperones - ATLAS Molecular Pharma

Next Previous
X
Search
Drug Profile

Research programme: small molecule pharmacological chaperones - ATLAS Molecular Pharma

Alternative Names: Pharmacological chaperones - ATLAS Molecular Pharma

Latest Information Update: 09 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atlas Molecular Pharma
  • Class Small molecules
  • Mechanism of Action FAHD1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Creutzfeldt-Jakob disease; Erythropoietic porphyria; Tyrosinaemia type I

Most Recent Events

  • 17 Jan 2022 Small molecule chaperones - ATLAS Molecular Pharma/CIC Biogune is available for licensing as of 17 Jan 2022. https://atlasmolecularpharma.com/about/
  • 17 Jan 2022 ATLAS Molecular Pharma plans preclinical studies in Liver disorders
  • 12 Nov 2021 Early research in Creutzfeldt-Jakob disease in Spain (unspecified route) (ATLAS Molecular Pharma pipeline, January 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top